article thumbnail

New tRNA tech aims to rewrite rare disease treatment

Drug Target Review

To do this, Alltrna leverages the unique biology of tRNA and its AI-enabled platform to design engineered tRNAs that can restore full-length protein production in diseases caused by shared genetic mutations, such as premature termination codons. Alltrna focuses on a mutation-driven approach.

Disease 80
article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

With more than 20 years of experience in business management, strategy, marketing and product management, Anis also has a research background in biotech, pharmaceutical and premier academic organisations. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News at Mary Ann Liebert, Inc. Biotechnol Prog.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Seevers Professor and Chair of Pharmacology, University of Michigan Medical School, will present a review of data from experiments conducted with TANGO ASOs in a mouse model of Dravet syndrome. December 8, 1:30 PM – 4:00 PM; Annual Fundamentals Symposium: Fundamentally New Ideas in Epilepsy Treatment and Research. Lori Isom, Ph.D.,

article thumbnail

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

At Elasmogen we have been able to capture, using the latest protein and genetic engineering techniques, the immune system of 10,000 shark equivalents in a test-tube. We then screened these for VNAR binders that block viral infection, and are delighted with the outcomes.”